Form 4: Akero Therapeutics CEO Andrew Cheng Acquires Shares Through Employee Stock Purchase Plan
Insider Transaction Report
Akero Therapeutics' President and CEO, Andrew Cheng, acquired 890 shares of common stock at $23.868 per share through the company's Employee Stock Purchase Plan, increasing his direct beneficial ownership to 550,757 shares.
Summary
- Andrew Cheng, President and CEO, and Director of Akero Therapeutics, Inc. (AKRO), acquired 890 shares of common stock.
- The acquisition occurred on June 30, 2025, at a price of $23.868 per share.
- These shares were purchased through the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan (ESPP).
- The purchase price represents 85% of the closing price of the Issuer's common stock on January 2, 2025.
- Following this transaction, Andrew Cheng directly beneficially owns 550,757 shares of Akero Therapeutics common stock.
- The transaction is exempt under SEC Rules 16b-3(c) and 16b-3(d) and was voluntarily reported.
Sentiment
Score: 7
Explanation: The acquisition of shares by a key executive, even through an ESPP, generally signals confidence in the company's future prospects. While it's a routine transaction, it's a positive signal of insider alignment.
Positives
- Insider acquisition of shares, indicating management confidence and alignment with shareholder interests.
- Participation in an Employee Stock Purchase Plan (ESPP) at a discounted price (85% of market price), which is a common benefit for employees.
- Increased direct beneficial ownership by a key executive.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Industry Context
This filing is a routine insider transaction report (Form 4) detailing an executive's acquisition of company shares through an employee stock purchase plan. It does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Employee Stock Purchase Plan Participation | Andrew Cheng acquired shares under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, which allows employees to purchase company stock at a discount. | June 30, 2025 | Enhances alignment between executive and shareholder interests; part of standard employee benefits and corporate compensation structure. |
Related Party Transactions
- Acquisition of 890 common shares by President and CEO Andrew Cheng from Akero Therapeutics, Inc. through the company's 2019 Employee Stock Purchase Plan at a discounted price of $23.868 per share.
Stakeholder Impact
- Shareholders: Increased insider ownership can be viewed positively as it aligns management interests with shareholders.
- Employees: Reinforces the existence and utilization of employee benefit plans like the ESPP, which can be a component of employee compensation and retention.
Key Dates
| Date | Description |
|---|---|
| 2019 | Year of establishment for the Akero Therapeutics, Inc. Employee Stock Purchase Plan. |
| January 2, 2025 | Date used to determine the closing price for the ESPP share purchase calculation. |
| June 30, 2025 | Date of the reported transaction where shares were acquired. |
| July 2, 2025 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
holdKeywords
Akero Therapeutics, AKRO, Andrew Cheng, Form 4, SEC filing, insider trading, stock acquisition, Employee Stock Purchase Plan, ESPP, common stock, corporate governance, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.